Descriptive Study of Cardiac Output During Rehydration With Recombinant Human Hyaluronidase in Pediatrics
| Status: | Completed |
|---|---|
| Conditions: | Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | Any - 3 |
| Updated: | 2/3/2018 |
| Start Date: | February 2010 |
| End Date: | November 2011 |
Phase IV Randomized Study of Hylenex or Standard IV Hydration in the Pediatric Population With Moderate Dehydration
The purpose of this study is to non-invasively study the reflective changes in cardiac output
as response to fluid therapy in the pediatric moderate hypovolemia/dehydrated pediatric
patients using sub-q rehydration using Hylenex augmented subcutaneous infusion of fluids and
electrolytes compared to intravenous methods.
as response to fluid therapy in the pediatric moderate hypovolemia/dehydrated pediatric
patients using sub-q rehydration using Hylenex augmented subcutaneous infusion of fluids and
electrolytes compared to intravenous methods.
This is an open-labeled, single-center Phase IV clinical trial. The study will consist of
patients with moderate hypovolemia/dehydration requiring parenteral rehydration. It is
expected that this study will describe the onset or change in cardiac output using Hylenex
augmented subcutaneous rehydration from ages 2 months up to 3 years and at a flow rate
satisfying clinical needs, especially in reference to changes in cardiac output observed in
standard intravenous rehydration.
patients with moderate hypovolemia/dehydration requiring parenteral rehydration. It is
expected that this study will describe the onset or change in cardiac output using Hylenex
augmented subcutaneous rehydration from ages 2 months up to 3 years and at a flow rate
satisfying clinical needs, especially in reference to changes in cardiac output observed in
standard intravenous rehydration.
Inclusion Criteria:
- patients presenting to the Emergency Department (ED) with moderate dehydration
(gorelick dehydration classification : presence of 3-6 moderate signs and symptoms)
requiring parenteral rehydration.
- Patient has not successfully received oral or IV fluids immediately prior to
enrollment
- patient's legally authorized representative has signed the informed consent and is
willing for the patient to receive Hylenex augmented sub-q rehydration
Exclusion Criteria:
- patient in shock or a life-threatening situation
- immunocompromised, history of abscess or cellulitis, abscess &/or cellulitis caused by
Methicillin-resistant Staphylococcus aureus (MRSA), family history of abscess or
cellulitis
- requires IV therapy for another indication
- has an indwelling catheter
- has already received rehydration therapy by IV route within the last 48 hours or
substantial oral fluid in the immediate time period of enrollment
- has a condition precluding sub-q injection or infusion site evaluation in the upper
middle back area or at another elected site of infusion
- has a reason for hospital admission or extended ED stay other than dehydration
- has an known hypersensitivity to hyaluronidase or another ingredient in the
formulation of Hylenex
- has a know hyponatremia < 130 milliequivalents per liter (mEq/L) or hypernatremia >155
mEq/L
- has a know hypokalemia <3.0 mEq/L
- has a medical condition likely to interfere with the patients ability to fully
complete the study protocol or the ability to have the protocol-specified assessments
- has a medical history, screening physical exam finding or historical clinical lab
result that in the opinion of the investigator would preclude the patients safe
participation in the is study or which might adversely effect the interpretation of
the study results
- patient participated in a study of any investigational drug or device within 230 days
prior to enrollment in this study
We found this trial at
1
site
Click here to add this to my saved trials
